Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Nadine KutschPhilipp GödelConrad-Amadeus VoltinMichael HallekChristof ScheidPeter BorchmannUdo HoltickPublished in: European journal of haematology (2024)
Patients with Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL-RT) face a dismal prognosis. A 51-year-old female patient diagnosed with CLL with deletion (17p) in 2009. CLL treatment included chemoimmunotherapy and targeted substances. DLBCL-RT was diagnosed in November 2016. After receiving an allogeneic hematopoietic stem cell transplantation, she relapsed in September 2019 and tisagenlecleucel was infused in December 2019. Cytokine release syndrome grade 2 was treated with two doses of tocilizumab and the patient was started on 140 mg ibrutinib in February 2020. Our patient remains in remission up to 4 years after CAR T-cell treatment.
Keyphrases
- diffuse large b cell lymphoma
- chronic lymphocytic leukemia
- stem cell transplantation
- case report
- epstein barr virus
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- acute myeloid leukemia
- high dose
- rheumatoid arthritis
- bone marrow
- disease activity
- low dose
- systemic lupus erythematosus
- rheumatoid arthritis patients
- juvenile idiopathic arthritis